NO20090304L - Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider - Google Patents

Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider

Info

Publication number
NO20090304L
NO20090304L NO20090304A NO20090304A NO20090304L NO 20090304 L NO20090304 L NO 20090304L NO 20090304 A NO20090304 A NO 20090304A NO 20090304 A NO20090304 A NO 20090304A NO 20090304 L NO20090304 L NO 20090304L
Authority
NO
Norway
Prior art keywords
release
inflammatory mediators
present
methods
inhibiting
Prior art date
Application number
NO20090304A
Other languages
English (en)
Norwegian (no)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of NO20090304L publication Critical patent/NO20090304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20090304A 2006-07-26 2009-01-20 Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider NO20090304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83323906P 2006-07-26 2006-07-26
PCT/US2007/074514 WO2008014414A2 (en) 2006-07-26 2007-07-26 Methods for attenuating release of inflammatory mediators and peptides useful therein

Publications (1)

Publication Number Publication Date
NO20090304L true NO20090304L (no) 2009-04-21

Family

ID=38982357

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090304A NO20090304L (no) 2006-07-26 2009-01-20 Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider

Country Status (22)

Country Link
US (6) US8999915B2 (zh)
EP (2) EP2053915B1 (zh)
JP (2) JP5378998B2 (zh)
KR (1) KR101599894B1 (zh)
CN (2) CN103990111B (zh)
AU (1) AU2007279193B2 (zh)
BR (1) BRPI0714953A2 (zh)
CA (2) CA2658949C (zh)
DK (2) DK2722052T3 (zh)
ES (2) ES2725599T3 (zh)
HK (2) HK1125793A1 (zh)
HR (1) HRP20140587T1 (zh)
IL (1) IL196667A (zh)
MX (1) MX2009000975A (zh)
NO (1) NO20090304L (zh)
PL (2) PL2053915T3 (zh)
PT (1) PT2053915E (zh)
RU (1) RU2423376C2 (zh)
SG (2) SG173411A1 (zh)
SI (1) SI2053915T1 (zh)
WO (1) WO2008014414A2 (zh)
ZA (1) ZA200900550B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606445A2 (pt) 2005-01-20 2009-03-10 Biomarck Pharmaceuticals Ltd inibidores de hipersecreÇço de mucina e mÉtodos de uso
JP5378998B2 (ja) 2006-07-26 2013-12-25 バイオマーク・フアーマシユーテイカルズ・リミテツド 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド
EP2445517B1 (en) * 2009-06-25 2014-07-30 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) * 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
DK2981279T3 (en) 2013-04-05 2019-03-25 Biomarck Pharmaceuticals Ltd MARCKS INHIBITOR PERIODS FOR INHIBITING METASTASES
US10189881B2 (en) 2013-07-26 2019-01-29 The Regents Of The University Of California MPS peptides and use thereof
WO2015095789A2 (en) * 2013-12-20 2015-06-25 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) * 2019-02-20 2020-11-20 한국외국어대학교 연구산학협력단 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
WO2023212443A1 (en) * 2022-04-25 2023-11-02 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating skin diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61265341A (ja) * 1985-05-17 1986-11-25 Kawasaki Heavy Ind Ltd Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
EP0759768A4 (en) 1994-04-07 2000-08-09 Proteinix Company VASOACTIVE COLON PEPTIDE
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
ES2230078T3 (es) 1999-02-24 2005-05-01 North Carolina State University Procedimientos y composiciones para alternar la secrecion de mucus.
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
ES2200787T3 (es) 1999-12-03 2004-03-16 Pfizer Products Inc. Derivados de acetileno como agentes antiinflamatorios/analgesicos.
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
ATE519493T1 (de) 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
JP2004049133A (ja) 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
BRPI0606445A2 (pt) 2005-01-20 2009-03-10 Biomarck Pharmaceuticals Ltd inibidores de hipersecreÇço de mucina e mÉtodos de uso
JP5378998B2 (ja) 2006-07-26 2013-12-25 バイオマーク・フアーマシユーテイカルズ・リミテツド 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド

Also Published As

Publication number Publication date
PL2053915T3 (pl) 2014-12-31
DK2722052T3 (en) 2019-04-29
US20200138898A1 (en) 2020-05-07
KR101599894B1 (ko) 2016-03-04
IL196667A (en) 2017-04-30
CA2842219A1 (en) 2008-01-31
CA2658949C (en) 2014-04-22
AU2007279193B2 (en) 2011-12-01
US20160030509A1 (en) 2016-02-04
US9827287B2 (en) 2017-11-28
HRP20140587T1 (hr) 2014-11-21
ES2488092T3 (es) 2014-08-26
IL196667A0 (en) 2011-08-01
CA2842219C (en) 2017-07-11
US20210260154A1 (en) 2021-08-26
RU2009106673A (ru) 2010-09-10
CN103990111A (zh) 2014-08-20
SG10201500418QA (en) 2015-03-30
EP2053915A4 (en) 2011-06-08
JP5378998B2 (ja) 2013-12-25
SI2053915T1 (sl) 2014-10-30
AU2007279193A1 (en) 2008-01-31
CN101516190A (zh) 2009-08-26
BRPI0714953A2 (pt) 2013-07-16
CN103990111B (zh) 2016-08-31
WO2008014414A3 (en) 2008-09-25
JP2013241428A (ja) 2013-12-05
EP2053915A2 (en) 2009-05-06
HK1125793A1 (zh) 2009-08-21
ZA200900550B (en) 2010-03-31
US20180036367A1 (en) 2018-02-08
CN101516190B (zh) 2014-06-11
CA2658949A1 (en) 2008-01-31
PL2722052T3 (pl) 2019-08-30
EP2722052A1 (en) 2014-04-23
SG173411A1 (en) 2011-08-29
US8999915B2 (en) 2015-04-07
JP2009544737A (ja) 2009-12-17
MX2009000975A (es) 2009-04-07
PT2053915E (pt) 2014-08-25
ES2725599T3 (es) 2019-09-25
HK1201190A1 (zh) 2015-08-28
US20090203620A1 (en) 2009-08-13
EP2722052B1 (en) 2019-03-20
KR20090037487A (ko) 2009-04-15
EP2053915B1 (en) 2014-06-11
DK2053915T3 (da) 2014-06-30
US20230293629A1 (en) 2023-09-21
JP5819889B2 (ja) 2015-11-24
WO2008014414A2 (en) 2008-01-31
RU2423376C2 (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
NO20090304L (no) Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider
WO2007103368A3 (en) Methods for regulating inflammatory mediators and peptides useful therein
PL2084543T3 (pl) Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
WO2007084419A3 (en) Inhibition of inflammatory cytokine production with tanshinones
WO2011024110A3 (en) Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
WO2009043889A3 (en) Oxadiazole derivatives
CL2007001335A1 (es) Anticuerpo anti cd40; acido nucleico que lo codifica; celula; cultivo celular; metodo de produccion; composicion farmaceutica; metodo para seleccionar un anticuerpo anti cd40; y su uso para tratar sintomas de un trastorno autoinmune y/o un trastorno inflamatorio y/o para reducir el rechazo al injerto y/o para el tratamiento de cancer positivos a cd40.
IN2012DN00338A (zh)
WO2011019986A3 (en) Processes for preparing pemetrexed
WO2006116381A3 (en) Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
WO2006065480A3 (en) Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
MX2009005194A (es) Derivados de purina 7-sustituidos para inmunosupresion.
TW200740844A (en) Novel MAdCAM antibodies
BRPI1007870A2 (pt) Bactéria isolada, método para produzir etanol, kit, cepa de e. Coli ly180, etanol, microarranjo, promotor de yqhd isolado, e, uso do promotor de yqhd.
WO2007082177A3 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
AP2010005310A0 (en) Methods and compositions for the removal of impurities and water from the Bayer process.
WO2012097238A3 (en) Il-27 antagonists for treating inflammatory diseases
WO2006133163A3 (en) Internal gettering by metal alloy clusters
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
WO2008030901A3 (en) Biomarker fragments for the detection of human bnp
WO2007130927A3 (en) Condensed tricyclic compounds as cgrp-receptor antagonists
WO2007131020A3 (en) Constrained compounds as cgrp-receptor antagonists
WO2008104957A3 (en) Novel polymorphic forms of milnacipran hydrochloride
WO2007075342A3 (en) Vaccine adjuvant

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application